Metabolism and disposition of pyrotinib in healthy male volunteers: covalent binding with human plasma protein

Pyrotinib is a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor that is used to treat HER2-positive breast cancer. In this study we investigated the metabolism and disposition of pyrotinib in six healthy Chinese men after a single oral dose of 402 mg of [(14)C]pyrotinib. At 240 h postdose...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Acta Pharmacol Sin
Main Authors: Meng, Jian, Liu, Xiao-yun, Ma, Sheng, Zhang, Hua, Yu, Song-da, Zhang, Yi-fan, Chen, Mei-xia, Zhu, Xiao-yu, Liu, Yi, Yi, Ling, Ding, Xiao-liang, Chen, Xiao-yan, Miao, Li-yan, Zhong, Da-fang
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6786348/
https://ncbi.nlm.nih.gov/pubmed/30382184
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41401-018-0176-6
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares